Back to Top Skip to main content Skip to sub-navigation

Pandemic Diseases

Medical Countermeasures (MCM) assumes a proactive, preventive approach to protect service members and their families who may be stationed or deployed in areas at elevated risk to both naturally occurring and manufactured emerging infectious diseases. MCM develops clinical use guidelines for vaccines, diagnostics and antiviral policies that protect the military, civilian personnel and beneficiaries to preserve U.S. combat capabilities and readiness. They also contribute to U.S. government-wide efforts to save lives reduce human suffering and slow the spread of infection. 

This includes managing and updating vaccine use policies to counter infectious disease threats such as smallpox and anthrax, and ensuring the safest and most effective preventive measures are in place to address adenovirus-associated illness and unique regional illnesses such as malaria, Japanese Encephalitis and leishmaniasis.

Photo of U.S. Air Force Staff Sgt. Jon Rigenoldus, 509th Medical Support Squadron medical lab technician, examines samples at Whiteman Air Force Base, Mo., March 18, 2015.

MCM interacts with DoD’s Chemical and Biological Defense Program, to assist in the following:  

  • Development of medical countermeasure requirements 
  • Acquisition processes
  • New product evaluations 
  • Determination of appropriate stockpiling 

MCM ensures that safe, effective medicines are in place and available when needed.

You also may be interested in...

Antibiotic Resistant Bacteria and How to Counter Them

Graphic image of a skeleton

Doctors are increasingly concerned about the potential for a “post-antibiotic” era when the highly effective drugs that we have relied on for many years to cure some of the most common illnesses will become ineffective.

Recommended Content:

Armed Forces Health Surveillance Division | Pandemic Diseases

U.S. Government Global Health Security Agenda Partners

U.S. Government Global Health Security Agenda Partners

Recommended Content:

Pandemic Diseases | Global Health Engagement

Chairman of the Joint Chiefs of Staff Instruction: Post-Deployment Policy for 21-day Controlled Monitoring


This instruction provides policy and guidance for the Services in the conduct of 21-day controlled monitoring of Service members and volunteering DoD civilian employees returning from the Ebola virus disease (EVD) outbreak area in West Africa.

Ebola Fact Sheet for Families of Deploying Personnel

Fact Sheet

The President and the Secretary of Defense have called upon the men and women of the US armed forces and other government personnel to provide critical support as part of the international response to the Ebola outbreaks in West Africa. This Fact Sheet highlights the actions that are in place prior to, during, and after deployment in order to protect our service members, families and communities.

Recommended Content:

Ebola | Operation United Assistance | Information for Military Families | Pandemic Diseases

Pre-Deployment, Deployment, and Post-Deployment Training, Screening, and Monitoring Guidance for Department of Defense Personnel Deployed to Ebola Outbreak Areas


Department of Defense (DoD) personnel (Service members and civilian employees)deployed to Centers for Disease Control and Prevention defined Ebola outbreak areas will complete pre and post-deployment screening and training requirements outlined in this memorandum and supplemented by United States Africa Command (USAFRICOM) guidance.

Detecting and Reporting DoD Cases of Ebola Virus Disease Infection


Guidance as of 17 OCT 2014 from the Department of Defese (AFHSC)for Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

CDC Ebola Fact Sheet

Fact Sheet

A fact sheet from the Centers for Disease Control describing Ebola, transimission, signs and symptoms, risk of exposure, diagnosis, treatment and prevention.

Recommended Content:

Ebola | Conditions and Treatments | Pandemic Diseases | Information for Military Families

Diagnostic Testing for MERS-CoV by DoD Laboratories

Fact Sheet

Diagnostic Testing for MERS-CoV by DoD Laboratories using the CDC Novel Coronavirus 2012 Real-Time RT-PCR Assay (MERS-CoV) For Emergency Use Only IAW Conditions of Authorization as specified in the FDA’s Emergency Use Authorization

Recommended Content:

Middle East Respiratory Syndrome Coronavirus | Pandemic Diseases
Showing results 1 - 8 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.